Compared with conventional therapeutic treatment, monoclonal immunotherapies are highly advantageous due to their high specificity and affinity towards well-defined targets and so are antibody-drug conjugates (ADCs). Moreover, consisting of the monoclonal antibody, a cytotoxic payload, and a molecular linker, ADC expands the therapeutic window of the conjugated drugs (payloads), which is usually highly toxic and diverse in their biochemical nature. https://www.creative-biolabs.com/adc/services.htm